Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 4, 2010, Pages 409-428

  Goebell, Peter J ^a   Knowles, Margaret A ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Genetic; Molecular alterations

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

BLADDER CANCER; BLADDER TUMOR; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CARCINOMA IN SITU; CHROMOSOME 9; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; NONINVASIVE PAPILLARY UROTHELIAL CARCINOMA; ONCOGENE RAS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UROTHELIUM; GENE; GENETICS; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

CARCINOMA IN SITU; CHROMOSOMES, HUMAN, PAIR 9; GENES, CDC; GENES, P53; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RETINOBLASTOMA PROTEIN; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77953819013     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.04.003     Document Type: Review

References (199)

1. Lopez-Beltran A. Bladder cancer: Clinical and pathological profile. Scand J Urol Nephrol 42 Suppl 218 (2008) 95-109
2. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
3. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
4. Knowles M.A. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol 42 4 (2008) 116-130
5. Johnson D.E., and Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60 (1993) 1-41
6. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23 (1999) 18-20
7. Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define 2 distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63 (2003) 8108-8112
8. Billerey C., Chopin D., Aubriot-Lorton M.H., et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 158 (2001) 1955-1959
9. Hernandez S., Lopez-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11 (2005) 5444-5450
10. Kimura T., Suzuki H., Ohashi T., et al. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92 (2001) 2555-2561
11. Rieger-Christ K.M., Mourtzinos A., Lee P.J., et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 98 (2003) 737-744
12. Sibley K., Cuthbert-Heavens D., and Knowles M.A. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20 (2001) 686-691
13. van Rhijn B.W., Lurkin I., Chopin D.K., et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9 (2003) 257-263
14. van Rhijn B.W., Lurkin I., Radvanyi F., et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
15. van Rhijn B.W., Montironi R., Zwarthoff E.C., et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198 (2002) 245-251
16. van Rhijn B.W., van Tilborg A.A., Lurkin I., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10 (2002) 819-824
17. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912-1921
18. Wallerand H., Bakkar A.A., de Medina S.G., et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: Contribution of exogenous versus endogenous carcinogens. Carcinogenesis 26 (2005) 177-184
19. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
20. Lamy A., Gobet F., Laurent M., et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176 (2006) 2686-2689
21. Jebar A.H., Hurst C.D., Tomlinson D.C., et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24 (2005) 5218-5225
22. Lindgren D., Liedberg F., Andersson A., et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25 (2006) 2685-2696
23. WHO. WHO classification tumors of the urinary system and male genital organs (2004), IARC Press, Lyon
24. Tomlinson D., Baldo O., and Knowles M.A. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213 (2007) 91-98
25. Matsumoto M., Ohtsuki Y., Ochii K., et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or noninvasive lesions. Oncol Rep 12 (2004) 967-971
26. Mhawech-Fauceglia P., Cheney R.T., Fischer G., et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 32 (2006) 231-237
27. Gomez-Roman J.J., Saenz P., Molina M., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 11 (2005) 459-465
28. Bernard-Pierrot I., Brams A., Dunois-Larde C., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27 (2006) 740-747
29. Martinez-Torrecuadrada J., Cifuentes G., Lopez-Serra P., et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11 (2005) 6280-6290
30. Hart K.C., Robertson S.C., Kanemitsu M.Y., et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19 (2000) 3309-3320
31. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66 (2006) 7401-7404
32. Platt F.M., Hurst C.D., Taylor C.F., et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15 (2009) 6008-6017
33. Hurst C.D., Zuiverloon T.C., Hafner C., et al. A SNaPshot assay for the rapid and simple detection of 4 common hotspot codon mutations in the PIK3CA gene. BMC Research Notes 2 (2009) 66
34. Mozaffari M., Hoogeveen-Westerveld M., Kwiatkowski D., et al. Identification of a region required for TSC1 stability by functional analysis of TSC1 missense mutations found in individuals with tuberous sclerosis complex. BMC Medical Genetic 10 (2009) 88
35. Nellist M., van den Heuvel D., Schluep D., et al. Missense mutations to the TSC1 gene cause tuberous sclerosis complex. Eur J Human Genet 17 (2009) 319-328
36. Henske E.P., Scheithauer B.W., Short M.P., et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Human Genet 59 (1996) 400-406
37. Hornigold N., Devlin J., Davies A.M., et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18 (1999) 2657-2661
38. Adachi H., Igawa M., Shiina H., et al. Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. J of Urol 170 (2003) 601-604
39. Cairns P., Shaw M.E., and Knowles M.A. Initiation of bladder cancer may involve deletion of a tumor-suppressor gene on chromosome 9. Oncogene 8 (1993) 1083-1085
40. Habuchi T., Devlin J., Elder P.A., et al. Detailed deletion mapping of chromosome 9q in bladder cancer: Evidence for 2 tumor suppressor loci. Oncogene 11 (1995) 1671-1674
41. Simoneau M., Aboulkassim T.O., LaRue H., et al. Four tumor suppressor loci on chromosome 9q in bladder cancer: Evidence for 2 novel candidate regions at 9q22.3 and 9q31. Oncogene 18 (1999) 157-163
42. van Tilborg A.A., Groenfeld L.E., van der Kwast T.H., et al. Evidence for 2 candidate tumor suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumor cell lines. Br J Cancer 80 (1999) 489-494
43. Knowles M.A., Habuchi T., Kennedy W., et al. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 63 (2003) 7652-7656
44. Pymar L.S., Platt F.M., Askham J.M., et al. Bladder tumor derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Human Molecular Genetics 17 (2008) 2006-2017
45. Carpten J.D., Faber A.L., Horn C., et al. A transforming mutation in the Pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
46. Askham J.M., Platt F., Chambers P.A., et al. AKT1 mutations in bladder cancer: Identification of a novel oncogenic mutation that can cooperate with E17K. Oncogene 29 (2010) 150-155
47. Hopman A.H., Kamps M.A., Speel E.J., et al. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 161 (2002) 1119-1125
48. Hartmann A., Schlake G., Zaak D., et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62 (2002) 809-818
49. Rosin M.P., Cairns P., Epstein J.I., et al. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 55 (1995) 5213-5216
50. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
51. Junker K., van Oers J.M., Zwarthoff E.C., et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 10 (2008) 1-7
52. Dyrskjot L., Kruhoffer M., Thykjaer T., et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64 (2004) 4040-4048
53. Dyrskjot L., Zieger K., Kruhoffer M., et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11 (2005) 4029-4036
54. Dyrskjot L., Zieger K., Real F.X., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 13 (2007) 3545-3551
55. Zieger K., Dyrskjøt L., Wiuf C., et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 11 (2005) 7709-7719
56. Zieger K., Marcussen N., Borre M., et al. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of 2 major pathways in bladder cancer development. Int J Cancer. 1 125 (2009) 2095-2103
57. Fujimoto K., Yamada Y., Okajima E., et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52 (1992) 1393-1398
58. Uchida T., Wada C., Ishida H., et al. p53 mutations and prognosis in bladder tumors. J Urol 153 (1995) 1097-1104
59. Petitjean A., Achatz M.I.W., Borresen-Dale A.L., et al. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
60. Soussi T., and Beroud C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 1 (2001) 233-240
61. Olivier M., Eeles R., Hollstein M., et al. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum Mutat 19 (2002) 607-614
62. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
63. Weisz L., Oren M., and Rotter V. Transcription regulation by mutant p53. Oncogene 26 (2007) 2202-2211
64. Strano S., Dell'Orso S., Di Agostino S., et al. Mutant p53: An oncogenic transcription factor. Oncogene 26 (2007) 2212-2219
65. Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene 26 (2007) 2145-2156
66. Malats N., Kogevinas M., Bustos A., et al. Bladder cancer and P53: An example of what should not be done in biomarker research. Int J Biol Markers 15 (2000) S30
67. Schmitz-Dräger B.J., Goebell P.J., Ebert T., et al. P53 immunohistochemistry as a prognostic marker in bladder cancer: A new toy for urologic scientists?. Eur Urol 38 (2000) 691-700
68. Zlotta A.R., and Schulman C.C. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 27 (2000) 179-189
69. Goebell P.J., Schmitz-Dräger B.J., Heydthausen M., et al., The International Study Initiative on Bladder Cancer (ISBC). A critical look at Antigen Retrieval and Choice of Antibodies for p53 Immunohistochemistry - Technical Aspects in the ISBC Combined Analysis. J Urol 167 (2002) 453
70. Dowell S.P., Lane D.P., and Hall P.A. The immunocytochemical detection of p53 protein in cytological specimens: Technical considerations. Cytopathology 5 (1994) 76-81
71. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6 (2005) 678-686
72. Schmitz-Dräger B.J., Goebell P.J., Heydthausen M., and The International Study Initiative on Bladder Cancer (ISBC). P53 immunohistochemistry in bladder cancer. Combined analysis: A way to go?. Urol Oncol 5 (2000) 204-215
73. Goebell P.J., Groshen S.G., and Schmitz-Dräger B.J. P53 Immunohistochemistry in Bladder Cancer - a new approach to an old story. Urol Oncol 28 (2010) 377-388
74. Hall P.A., and Lane D.P. p53 in tumor pathology: Can we trust immunohistochemistry?. Revisited! J Pathol 172 (1994) 1-4
75. George B., Datar R.H., Wu L., et al. p53 gene and protein status: The role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 25 (2007) 5352-5358
76. Kelsey K.T., Hirao T., Schned A., et al. A population-based study of Immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer 90 (2004) 1572-1576
77. Lopez-Knowles E., Hernandez S., Kogevinas M., et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 12 (2006) 6029-6036
78. Simon R., Struckmann K., Schraml P., et al. Amplification pattern of 12q13 q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21 (2002) 2476-2483
79. Liang H., Atkins H., Abdel-Fattah R., et al. Genomic organization of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene 338 (2004) 217-223
80. Schlott T., Quentin T., Korabiowska M., et al. Alteration of the MDM2-p73-P14ARF pathway related to tumor progression during urinary bladder carcinogenesis. Int J Mol Med 14 (2004) 825-836
81. Sanchez-Carbayo M., Socci N.D., Kirchoff T., et al. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res 13 (2007) 3215-3220
82. Markl I.D., and Jones P.A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 58 (1998) 5348-5353
83. Chang L.L., Yeh W.T., Yang S.Y., et al. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 170 (2003) 595-600
84. Berggren P., Kumar R., Sakano S., et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 9 (2003) 235-242
85. Le Frère-Belda M.A., Gil Diez de Medina S., Daher A., et al. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status. Hum Pathol 35 (2004) 817-824
86. Kawamoto K., Enokida H., Gotanda T., et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 339 (2006) 790-796
87. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90 (1998) 1072-1079
88. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
89. Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 183 (2010) 68-75
90. Cairns P., Proctor A.J., and Knowles M.A. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 6 (1991) 2305-2309
91. Benedict W.F., Lerner S.P., Zhou J., et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18 (1999) 1197-1203
92. Shariat S.F., Tokunaga H., and Zhou J. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
93. Cordon-Cardo C., Wartinger D., Petrylak D., et al. Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84 (1992) 1251-1256
94. Logothetis C.J., Xu H.-J., Ro J.Y., et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84 (1992) 1256-1261
95. Hurst C.D., Tomlinson D.C., Williams S.V., et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumors with 6p22 amplification. Oncogene 27 (2008) 2716-2727
96. Feber A., Clark J., Goodwin G., et al. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene 23 (2004) 1627-1630
97. Oeggerli M., Tomovska S., Schraml P., et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene 23 (2004) 5616-5623
98. Steinthorsdottir V., Thorleifsson G., Reynisdottir I., et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39 (2007) 770-775
99. Oeggerli M., Schraml P., Ruiz C., et al. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oncogene 25 (2006) 6538-6543
100. Olsson A.Y., Feber A., Edwards S., et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 26 (2007) 1028-1037
101. Xu H.J., Cairns P., Hu S.X., et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53 (1993) 781-784
102. Adams J., Williams S.V., Aveyard J.S., et al. Loss of heterozygosity analysis and DNA copy number measurement on 8p in bladder cancer reveals 2 mechanisms of allelic loss. Cancer Res 65 (2005) 66-75
103. Choi C., Kim M.H., Juhng S.W., et al. Loss of heterozygosity at chromosome segments 8p22 and 8p11.2 21.1 in transitional-cell carcinoma of the urinary bladder. Int J Cancer 86 (2000) 501-505
104. Stoehr R., Wissmann C., Suzuki H., et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest 16 (2004) 465-478
105. Takle L.A., and Knowles M.A. Deletion mapping implicates 2 tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 12 (1996) 1083-1087
106. Thompson T.E., Rogan P.K., Risinger J.I., et al. Splice variants but not mutations of DNA polymerase beta are common in bladder cancer. Cancer Res 62 (2002) 3251-3256
107. Adams J., Cuthbert-Heavens D., Bass S., et al. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett 220 (2005) 137-144
108. Eydmann M.E., and Knowles M.A. Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenet 93 (1997) 167-171
109. Knowles M.A., Aveyard J.S., Taylor C.F., et al. Mutation analysis of the 8p candidate tumor suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 225 (2005) 121-130
110. Blaveri E., Brewer J.L., Roydasgupta R., et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 11 (2005) 7012-7022
111. Richter J., Beffa L., Wagner U., et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 153 (1998) 1615-1621
112. Aveyard J.S., Skilleter A., Habuchi T., et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80 (1999) 904-908
113. Cappellen D., Gil Diez de Medina S., Chopin D., et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 14 (1997) 3059-3066
114. Kagan J., Liu J., Stein J.D., et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene 16 (1998) 909-913
115. Wang D.S., Rieger-Christ K., Latini J.M., et al. Molecular analysis of PTEN and MXI1 in primary bladder carcinoma. Int J Cancer 88 (2000) 620-625
116. Liu J., Babaian D.C., Liebert M., et al. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol Carcinog 29 (2000) 143-150
117. Kwabi-Addo B., Giri D., Schmidt K., et al. Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98 (2001) 11563-11568
118. Kwon C.H., Zhao D., Chen J., et al. PTEN haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68 (2008) 3286-3294
119. Gildea J.J., Herlevsen M., Harding M.A., et al. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatide activity. Oncogene 23 (2004) 6788-6797
120. Tsuruta H., Kishimoto H., Sasaki T., et al. Hyperplasia and carcinomas in PTEN-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 66 (2006) 8389-8396
121. Coombs L.M., Pigott D.A., Sweeney E., et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63 (1991) 601-608
122. Lonn U., Lonn S., Friberg S., et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1 (1995) 1189-1194
123. Miyamoto H., Kubota Y., Noguchi S., et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55 (2000) 679-683
124. Sauter G., Moch H., Moore D., et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53 (1993) 2199-2203
125. Simon R., Atefy R., Wagner U., et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107 (2003) 764-772
126. Hovey R.M., Chu L., Balazs M., et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58 (1998) 3555-3560
127. Simon R., Burger H., Semjonow A., et al. Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol 17 (2000) 1025-1029
128. Veltman J.A., Fridlyand J., Pejavar S., et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 63 (2003) 2872-2880
129. Simon R., Eltze E., Schafer K.L., et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 61 (2001) 355-362
130. Blaveri E., Simko J.P., Korkola J.E., et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 11 (2005) 4044-4055
131. Schaffer A.A., Simon R., Desper R., et al. Tree models for dependent copy number changes in bladder cancer. Int J Oncol 18 (2001) 349-354
132. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57 (2010) 60-70
133. Fritsche H.M., Burger M., Svatek R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort. Eur Urol 57 (2010) 300-309
134. Inci K., Guliyev F., Bilen C.Y., et al. Incidental diagnosis of transitional cell carcinoma during percutaneous nephrolithotomy. Urol Int 83 (2009) 291-294
135. Emiliozzi P., Pansadoro A., and Pansadoro V. The optimal management of T1G3 bladder cancer. BJU Int 102 (2008) 1265-1273
136. Soloway M.S., Lee C.T., Steinberg G.D., et al. Difficult decisions in urologic oncology: Management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 25 (2007) 338-340
137. Metwalli A.R., and Kamat A.M. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 6 (2006) 1283-1294
138. Witjes J.A. Management of the first recurrence of T1G3 bladder cancer: Does intravesical chemotherapy deserve a chance?. Urol Oncol 27 (2009) 322-324
139. Halachmi S., Moskovitz B., Maffezzini M., et al. Intravesical mitomycin c combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol (2009) 322-324 Epub ahead of print
140. Kulkarni G.S., Alibhai S.M., Finelli A., et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115 (2009) 5450-5459
141. Herr H.W. High-risk, high-grade (T1G3) bladder cancer: Models versus reality. Cancer 115 (2009) 5366-5367
142. Park J., Song C., Hong J.H., et al. Prognostic significance of nonpapillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 27 (2009) 277-283
143. Thalmann G. Organ preservation for T1G3 bladder cancer: Is it feasible?. Eur Urol 53 (2008) 27-29
144. Queipo-Zaragoza J.A., Ruiz-Cerda J.L., Vera-Donoso C.D., et al. Prognostic value of p53, Ki-67, microstaging and microvessel density in pT1G3 bladder tumors: Creation of risk groups for progression. Scand J Urol Nephrol 41 (2007) 283-289
145. Serretta V, Morgia G, Altieri V, et al.; members of Gruppo Studi Tumori Urologici (GSTU) Foundation (2010). A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int (in press).
146. Dalbagni G., Vora K., Kaag M., et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. Eur Urol 56 (2009) 903-910
147. Richter J., Wagner U., Schraml P., et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res 59 (1999) 5687-5691
148. van Tilborg A.A., de Vries A., de Bont M., et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9 (2000) 2973-2980
149. van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911-1914
150. Richter J., Jiang F., Gorog J.P., et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57 (1997) 2860-2864
151. Linnenbach A.J., Pressler L.B., Seng B.A., et al. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Hum Mol Genet 2 (1993) 1407-1411
152. Tsai Y.C., Nichols P.W., Hiti A.L., et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 50 (1990) 44-47
153. Fadl-Elmula I., Gorunova L., Mandahl N., et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 29 (2000) 256-265
154. Gibas Z., Prout Jr. G.R., Connolly J.G., et al. Nonrandom chromosomal changes in transitional cell carcinoma of the bladder. Cancer Res 44 (1984) 1257-1264
155. Cairns P., Mao L., Merlo A., et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265 (1994) 415-417
156. Devlin J., Keen A.J., and Knowles M.A. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFN-A. Oncogene 9 (1994) 2757-2760
157. Orlow I., Lacombe L., Hannon G.J., et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87 (1995) 1524-1529
158. Williamson M.P., Elder P.A., Shaw M.E., et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4 (1995) 1569-1577
159. Chapman E.J., Harnden P., Chambers P., et al. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 11 (2005) 5740-5747
160. Bartoletti R., Cai T., Nesi G., et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 143 (2007) 422-427
161. Berggren de Verdier P.J., Kumar R., Adolfsson J., et al. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand J Urol Nephrol 40 (2006) 363-369
162. Aboulkassim T.O., LaRue H., Lemieux P., et al. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 22 (2003) 2967-2971
163. McGarvey T.W., Maruta Y., Tomaszewski J.E., et al. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 17 (1998) 1167-1172
164. Habuchi T., Luscombe M., Elder P.A., et al. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32 q33. Genomics 48 (1998) 277-288
165. Nishiyama H., Hornigold N., Davies A., et al. A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32 q33. Genomics 59 (1999) 335-338
166. Stadler W.M., Steinberg G., Yang X., et al. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 7 (2001) 1676-1682
167. Habuchi T., Yoshida O., and Knowles M.A. A novel candidate tumor suppressor locus at 9q32 33 in bladder cancer: Localization of the candidate region within a single 840kb YAC. Hum Mol Genet 6 (1997) 913-919
168. Nishiyama H., Takahashi T., Kakehi Y., et al. Homozygous deletion at the 9q32 33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosomes Cancer 26 (1999) 171-175
169. Fujiwara H., Emi M., Nagai H., et al. Definition of a 1-Mb homozygous deletion at 9q32 q33 in a human bladder-cancer cell line. J Hum Genet 46 (2001) 372-377
170. Habuchi T., Takahashi T., Kakinuma H., et al. Hypermethylation at 9q32 33 tumor suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20 (2001) 531-537
171. Salem C., Liang G., Tsai Y.C., et al. Progressive increases in de novo Methylation of CpG islands in bladder cancer. Cancer Res 60 (2000) 2473-2476
172. Nishiyama H., Gill J.H., Pitt E., et al. Negative regulation of G(1)/S transition by the candidate bladder tumor suppressor gene DBCCR1. Oncogene 20 (2001) 2956-2964
173. Hirao S., Hirao T., Marsit C.J., et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer 104 (2005) 1918-1923
174. Simoneau M., LaRue H., Aboulkassim T.O., et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: Identification of 4 regions of prognostic interest. Oncogene 19 (2000) 6317-6323
175. Edwards J., Duncan P., Going J.J., et al. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 196 (2002) 380-385
176. van Tilborg A.A., de Vries A., de Bont M., et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9 (2000) 2973-2980
177. Louhelainen J., Wijkstrom H., and Hemminki K. Initiation development modeling of allelic losses on chromosome 9 in multifocal bladder cancer. Eur J Cancer 36 (2000) 1441-1451
178. van Tilborg A.A., de Vries A., de Bont M., et al. The random development of LOH on chromosome 9q in superficial bladder cancers. J Pathol 198 (2002) 352-358
179. Keen A.J., and Knowles M.A. Definition of 2 regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9 (1994) 2083-2088
180. Ruppert J.M., Tokino K., and Sidransky D. Evidence for 2 bladder cancer suppressor loci on human chromosome 9. Cancer Res 53 (1993) 5093-5095
181. Modlich O., Prisack H.B., Pitschke G., et al. Identifying superficial, muscle invasive, and metastasizing transitional cell carcinoma of the bladder: Use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10 (2004) 3410-3421
182. Sanchez-Carbayo M., Socci N.D., Lozano J., et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24 (2006) 778-789
183. Koed K., Wiuf C., Christensen L.L., et al. High-density single nucleotide polymorphism array defines novel stage and location dependent allelic imbalances in human bladder tumors. Cancer Res 65 (2005) 34-45
184. Hoque M.O., Lee C.C., Cairns P., et al. Genome-wide genetic characterization of bladder cancer: A comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 63 (2003) 2216-2222
185. Goebell P.J. Outcomes and response to therapy in bladder cancer - are biomarkers of any help?. Minerva Urol Nefrol 61 (2009) 91-107
186. Takahashi T., Habuchi T., Kakehi Y., et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 58 (1998) 5835-5841
187. Hoglund M., Sall T., Heim S., et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 61 (2001) 8241-8246
188. Bulashevska S., Szakacs O., Brors B., et al. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data. Int J Cancer 110 (2004) 850-856
189. Hoglund M., Frigyesi A., Sall T., et al. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 42 (2005) 327-341
190. Sung M.T., Maclennan G.T., Lopez-Beltran A., et al. Natural history of urothelial inverted papilloma. Cancer 107 (2006) 2622-2627
191. Sung M.T., Eble J.N., Wang M., et al. Inverted papilloma of the urinary bladder: A molecular genetic appraisal. Mod Pathol 19 (2006) 1289-1294
192. Eiber M., van Oers J.M., Zwarthoff E.C., et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol 31 (2007) 938-946
193. Hartmann A., Moser K., Kriegmair M., et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154 (1999) 721-727
194. Obermann E.C., Junker K., Stoehr R., et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199 (2003) 50-57
195. van Oers J.M., Adam C., and Denzinger S. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119 (2006) 1212-1215
196. Muto S., Horie S., Takahashi S., et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 60 (2000) 4021-4025
197. Kattan M.W. Prediction models for transitional cell carcinoma. J Urol 182 (2009) 423-424
198. Vickers A. Prediction models in urology: Are they any good, and how would we know anyway?. Eur Urol 57 (2010) 571-573
199. Hemingway H., Riley R.D., and Altman D.G. Ten steps towards improving prognosis research. BMJ 339 (2009) b4184